<DOC>
	<DOCNO>NCT02199951</DOCNO>
	<brief_summary>WHO recommend use artemisinin-based combination therapy ( ACTs ) treatment uncomplicated malaria stem falciparum malaria drug resistance . New ACTs enter African market use public health care system . The collection safety data risk evaluation observational data critical order ass risk/benefit profile ACT life cycle provide information best use . Additionally need assess impact introduction new ACT evolution efficacy malaria morbidity mortality . Dihydroartemisinin/Piperaquine ( DHA/PQP ) new ACT approve European Medical Agency number African country . This phase IV observational evaluation clinical safety fixed-dose DHA/PQP ( Eurartesim® ) public health facility within select Health Demographic Surveillance Centres Burkina Faso ( Nouna ) , Mozambique ( Manhica ) , Ghana ( Dodowa , Kintampo , Navrongo ) , Tanzania ( Rufiji ) African country add . Eurartesim® use first-line treatment uncomplicated malaria objective evaluate safety Eurartesim® use usual condition 10,000 patient . Patients &gt; 6 month 5 kg except pregnant woman enrol Eurartesim® administer single daily dose regimen 3 day . Patients contact Day 5 ( ± 2 day ) treatment , assess recovery adverse event .</brief_summary>
	<brief_title>Introduction Eurartesim® Burkina Faso , Mozambique , Ghana Tanzania</brief_title>
	<detailed_description>Study perform public health facility 7 select HDSS centre ( Health Demographic Surveillance site ) within HDSS Burkina Faso ( 1 ) , Mozambique ( 1 ) , Ghana ( 3 ) , Tanzania ( 2 ) , Eurartesim® use first-line treatment uncomplicated malaria episode . Primary : Evaluate safety Eurartesim® use usual condition 10,000 patient sign symptom uncomplicated malaria confirm parasitological diagnosis ( Microscopy/Rapid Diagnostic Test ) , test available , WHO diagnostic criterion . Main Secondary : Intensive assessment nest subset 1,000 patient evaluate effect administration Eurartesim® blood biochemistry , full blood count , WBC differential count QTc interval . QTc interval piperaquine concentration relationship also investigate selected center . Other Secondaries : Although expect vast majority patient infect P. falciparum , comparison clinical tolerability Plasmodium falciparum infect patient versus patient infected Plasmodia , confirm thick blood smear result , carried-out nest subset 1,000 patient . Assessment relationship occurrence Adverse Events administration concomitant medication also evaluate subset 1,000 patient . All patient visit Health facility HDSS area diagnosis uncomplicated malaria ( accord WHO criterion ) suspect confirmed parasitological diagnosis ( Microscopy/Rapid Diagnostic Test ) sign inform consent/assent ( parent/guardian child 18 year old ) include study . In subset 1,000 patient , presence Plasmodia specie confirm microscopically . A thick blood smear prepare microscopic diagnosis patient . Eurartesim® tablet prescribe patient ( parents/guardians , patient child ) meeting protocol inclusion criterion result thick blood smear know . The patient contact Day 5 ( ± 2 day ) , order capture recovery status experience adverse event . A visit community health agent schedule case information collect telephone contact consider incomplete unreliable one . Special procedure follow case serious and/or severe adverse event event classify special interest ( see specific section ) . The subset 1,000 patient intensively followed-up . These patient haematology ( Hb full blood count ( RBC , WBC differential count ) ) standard biochemistry ( BUN , Creatinine , ALT/AST , Bilirubine , electrolytes ( K+ Cl- ) ) undertaken Day 1 ( drug administration ) , Day 3 ( 3-4 hour last dose treatment ) , Day 7 . If result abnormal clinically relevant , blood examination repeat normalization . In 1000 patient , plasma sample collect Day 1 ( drug administration ) , twice Day 3 ( i.e . 3-4 hour last drug administration ) well Day 7 ass plasma PQ concentration . From blood drawing centrifugation , three drop whole blood spot filter paper . These filter paper utilized determine whole blood piperaquine concentration Dry Blood Spot methodology ( validated analytical method determination settle time study course ) . ECGs undertaken Day 1 ( drug administration ) , twice Day 3 ( i.e . 3-4 hour last drug administration ) well Day 7 ( ECG Day 1 Day 3 last drug administration collect triplicate ) ; safety information collect visit . If QTcF ( QT correct Fridericia 's formula ) value assess Day 3 last dose 500 m , Eurartesim® withhold QTcF return 480 m within 6 hour . Thereafter , Eurartesim® cycle may complete frequent QTc monitoring base medical judgment . If QTcF return 480 m within 6 hour , another antimalarial therapy consider . The occurrence adverse event solicit subset 1,000 patient Days 3 7 follow administration Eurartesim® well additional visit . All patient study cardiac event special interest ( see ) ECG perform . Patients ask report health facility HDSS adverse event occur Day 5 ( ± 2 day ) contact within 28 day start Eurartesim® intake . Female patient encourage communicate study team get pregnant within period two month start Eurartesim® treatment . In case , information evolution pregnancy collect 3 , 6 , 9 month delivery ( 6 14 week ) . Information drug take pregnancy well AEs/SAEs/AESIs health status newborn/s collect . Patients instructed take Eurartesim® dose regimen one administration every 24 hour period three day , i.e . Day 1 , 24 hour ( Day 2 ) 48 hour ( Day 3 ) first administration . The dose base patient body weight . Two strengths Eurartesim® provide facilitate dose child adult : 20/160mg 40/320mg DHA PQP respectively . The patient instruct take Eurartesim® water , least three hour three hour food intake ( i.e . three hour previous food intake food intake follow three hour Eurartesim® administration ) . To facilitate drug administration small child , tablet crush spoon give water . If vomiting occurs within 30 min drug administration , dose re-administered . If vomiting occurs within 30 60 min , half dose re-administered . Re-dosing attempted .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Uncomplicated malaria ( Plasmodia specie ) diagnose per national policy line WHO recommendation ( history fever previous 24 h and/or presence anaemia , pallor palm appear reliable sign young child ) . Confirmation malaria parasitological diagnosis RDT encourage absence prevent patient enrol . Age ≥ 6 month weight ≥ 5 kg . Capability take oral medication . Ability willingness participate base sign informed consent ( parent guardian sign child 18 year old ) , verbal consent give front witness signing informed consent , access health facility . The patient comply schedule followup visit . • Known allergy artemisinin piperaquine . Known pregnancy . Lactating woman exclude antimalarial treatment available Complicated malaria . Taking medicinal product know prolong QTc interval . These include ( limited ) : Antiarrhythmics ( e.g . amiodarone , disopyramide , dofetilide , ibutilide , procainamide , quinidine , hydroquinidine , sotalol ) . Neuroleptics ( e.g . phenothiazine , sertindole , sultopride , chlorpromazine , haloperidol , mesoridazine , pimozide , thioridazine ) , antidepressive agent . Certain antimicrobial agent , include agent follow class : macrolides ( e.g . erythromycin , clarithromycin ) , fluoroquinolones ( e.g . moxifloxacin , sparfloxacin ) , imidazole triazole antifungal agent , also pentamidine saquinavir . Certain nonsedating antihistamine ( e.g . terfenadine , astemizole , mizolastine ) . Cisapride , droperidol , domperidone , bepridil , diphemanil , probucol , levomethadyl , methadone , vinca alkaloid , arsenic trioxide . Have take DHA/PQP dose previous four week . Family history sudden unexplained death , personal family history predispose cardiac condition arrhythmia/QT prolongation ( include congenital long QT syndrome , arrhythmia , QTc interval great 450 millisecond either Bazett Fridericia correction ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Uncomplicated Malaria</keyword>
	<keyword>dihydroartemisinin</keyword>
	<keyword>piperaquine</keyword>
</DOC>